nature.com search

Loading Filters

Showing 1–30 of 30 results

Loading Filters

21 March 2014
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8
- H Becker
- , K Maharry
- , K Mrózek
- , S Volinia
- , A-K Eisfeld
- , M D Radmacher
- , J Kohlschmidt
- , K H Metzeler
- , S Schwind
- , S P Whitman
- , J H Mendler
- , Y-Z Wu
- , D Nicolet
- , P Paschka
- , B L Powell
- , T H Carter
- , M Wetzler
- , J E Kolitz
- , A J Carroll
- , M R Baer
- , M A Caligiuri
- , R M Stone
- , G Marcucci
- & C D Bloomfield
Leukemia 28 , 1754–1758

Rights & permissionsfor article Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 . Opens in a new window.
24 March 2017
No evidence for microsatellite instability in acute myeloid leukemia
- C J Walker
- , A-K Eisfeld
- , L K Genutis
- , M Bainazar
- , J Kohlschmidt
- , K Mrózek
- , A J Carroll
- , J E Kolitz
- , B L Powell
- , E S Wang
- , R M Stone
- , R Bundschuh
- , A de la Chapelle
- & C D Bloomfield
Leukemia 31 , 1474–1476

Rights & permissionsfor article No evidence for microsatellite instability in acute myeloid leukemia . Opens in a new window.
25 May 2016
Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
- H Wu
- , A Wang
- , Z Qi
- , X Li
- , C Chen
- , K Yu
- , F Zou
- , C Hu
- , W Wang
- , Z Zhao
- , J Wu
- , J Liu
- , X Liu
- , L Wang
- , W Wang
- , S Zhang
- , R M Stone
- , I A Galinsky
- , J D Griffin
- , D Weinstock
- , A Christodoulou
- , H Wang
- , Y Shen
- , Z Zhai
- , E L Weisberg
- , J Liu
- & Q Liu
Leukemia 30 , 2112–2116

Rights & permissionsfor article Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML . Opens in a new window.
Research | 13 September 2016
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
- W Blum
- , B L Sanford
- , R Klisovic
- , D J DeAngelo
- , G Uy
- , B L Powell
- , W Stock
- , M R Baer
- , J E Kolitz
- , E S Wang
- , E Hoke
- , K Mrózek
- , J Kohlschmidt
- , C D Bloomfield
- , S Geyer
- , G Marcucci
- , R M Stone
- & R A Larson
Leukemia 31 , 34–39

Rights & permissionsfor article Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) . Opens in a new window.
24 May 2013 | Open
Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies
- H Singh
- , A A Lane
- , M Correll
- , B Przychodzen
- , D B Sykes
- , R M Stone
- , K K Ballen
- , P C Amrein
- , J Maciejewski
- & E C Attar
Blood Cancer Journal 3 , e117–e117

Rights & permissionsfor article Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies . Opens in a new window.
3 July 2015
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
- H Wu
- , C Hu
- , A Wang
- , E L Weisberg
- , W Wang
- , C Chen
- , Z Zhao
- , K Yu
- , J Liu
- , J Wu
- , A Nonami
- , L Wang
- , B Wang
- , R M Stone
- , S Liu
- , J D Griffin
- , J Liu
- & Q Liu
Leukemia 30 , 754–757

Rights & permissionsfor article Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML . Opens in a new window.
Editorial | 12 August 2009
Iron chelation therapy in myelodysplastic syndrome — Cui bono?
- A Tefferi
- & R M Stone
Leukemia 23 , 1373–1373

Rights & permissionsfor article Iron chelation therapy in myelodysplastic syndrome — Cui bono? . Opens in a new window.
Research | 23 May 2016 | Open
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
- J Etchin
- , A Berezovskaya
- , A S Conway
- , I A Galinsky
- , R M Stone
- , E Baloglu
- , W Senapedis
- , Y Landesman
- , M Kauffman
- , S Shacham
- , J C Y Wang
- & A T Look
Leukemia 31 , 143–150

Rights & permissionsfor article KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells . Opens in a new window.
10 March 2017 | Open
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
- G L Uy
- , M P Rettig
- , R M Stone
- , M Y Konopleva
- , M Andreeff
- , K McFarland
- , W Shannon
- , T R Fletcher
- , T Reineck
- , W Eades
- , K Stockerl-Goldstein
- , C N Abboud
- , M A Jacoby
- , P Westervelt
- & J F DiPersio
Blood Cancer Journal 7 , e542–e542

Rights & permissionsfor article A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia . Opens in a new window.
20 July 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2
- A-K Eisfeld
- , J Kohlschmidt
- , K Mrózek
- , J S Blachly
- , D Nicolet
- , K Kroll
- , S Orwick
- , A J Carroll
- , R M Stone
- , A de la Chapelle
- , J C Byrd
- & C D Bloomfield
Leukemia 30 , 2254–2258

Rights & permissionsfor article Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2 . Opens in a new window.
Research | 21 March 2016
Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?
- A El-Jawahri
- , H T Kim
- , D P Steensma
- , A M Cronin
- , R M Stone
- , C D Watts
- , Y-B Chen
- , C S Cutler
- , R J Soiffer
- & G A Abel
Bone Marrow Transplantation 51 , 1121–1126

Rights & permissionsfor article Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? . Opens in a new window.
16 December 2015
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)
- B Bhatnagar
- , J S Blachly
- , J Kohlschmidt
- , A-K Eisfeld
- , S Volinia
- , D Nicolet
- , A J Carroll
- , A W Block
- , J E Kolitz
- , R M Stone
- , K Mrózek
- , J C Byrd
- & C D Bloomfield
Leukemia 30 , 1586–1589

Rights & permissionsfor article Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) . Opens in a new window.
15 June 2015
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
- R Sood
- , N F Hansen
- , F X Donovan
- , B Carrington
- , D Bucci
- , B Maskeri
- , A Young
- , N S Trivedi
- , J Kohlschmidt
- , R M Stone
- , M A Caligiuri
- , S C Chandrasekharappa
- , G Marcucci
- , J C Mullikin
- , C D Bloomfield
- & P Liu
Leukemia 30 , 501–504

Rights & permissionsfor article Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia . Opens in a new window.
Research | 10 April 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
- A Hochhaus
- , M Baccarani
- , M Deininger
- , J F Apperley
- , J H Lipton
- , S L Goldberg
- , S Corm
- , N P Shah
- , F Cervantes
- , R T Silver
- , D Niederwieser
- , R M Stone
- , H Dombret
- , R A Larson
- , L Roy
- , T Hughes
- , M C Müller
- , R Ezzeddine
- , A M Countouriotis
- & H M Kantarjian
Leukemia 22 , 1200–1206

Rights & permissionsfor article Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib . Opens in a new window.
Research | 27 April 2012
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- R M Stone
- , T Fischer
- , R Paquette
- , G Schiller
- , C A Schiffer
- , G Ehninger
- , J Cortes
- , H M Kantarjian
- , D J DeAngelo
- , A Huntsman-Labed
- , C Dutreix
- , A del Corral
- & F Giles
Leukemia 26 , 2061–2068

Rights & permissionsfor article Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia . Opens in a new window.
19 March 2003
Induction and postremission therapy: new agents
- R M Stone
Leukemia 17 , 496–498

Rights & permissionsfor article Induction and postremission therapy: new agents . Opens in a new window.
Research | 6 August 2007
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
- V Nardi
- , T Raz
- , X Cao
- , C J Wu
- , R M Stone
- , J Cortes
- , M W N Deininger
- , G Church
- , J Zhu
- & G Q Daley
Oncogene 27 , 775–782

Rights & permissionsfor article Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors . Opens in a new window.
Comments and Opinion | 21 October 2004
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)
- R L Levine
- , M Wadleigh
- , D W Sternberg
- , I Wlodarska
- , I Galinsky
- , R M Stone
- , D J DeAngelo
- , D Gary Gilliland
- & J Cools
Leukemia 19 , 27–30

Rights & permissionsfor article KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) . Opens in a new window.
Research | 15 November 2016
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia
- A-K Eisfeld
- , J Kohlschmidt
- , S Schwind
- , D Nicolet
- , J S Blachly
- , S Orwick
- , C Shah
- , M Bainazar
- , K W Kroll
- , C J Walker
- , A J Carroll
- , B L Powell
- , R M Stone
- , J E Kolitz
- , M R Baer
- , A de la Chapelle
- , K Mrózek
- , J C Byrd
- & C D Bloomfield
Leukemia 31 , 1278–1285

Rights & permissionsfor article Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia . Opens in a new window.
Research | 10 September 2014
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
- C Niederwieser
- , J Kohlschmidt
- , S Volinia
- , S P Whitman
- , K H Metzeler
- , A-K Eisfeld
- , K Maharry
- , P Yan
- , D Frankhouser
- , H Becker
- , S Schwind
- , A J Carroll
- , D Nicolet
- , J H Mendler
- , J P Curfman
- , Y-Z Wu
- , M R Baer
- , B L Powell
- , J E Kolitz
- , J O Moore
- , T H Carter
- , R Bundschuh
- , R A Larson
- , R M Stone
- , K Mrózek
- , G Marcucci
- & C D Bloomfield
Leukemia 29 , 567–575

Rights & permissionsfor article Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia . Opens in a new window.
Research | 14 June 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia
- K H Metzeler
- , K Maharry
- , J Kohlschmidt
- , S Volinia
- , K Mrózek
- , H Becker
- , D Nicolet
- , S P Whitman
- , J H Mendler
- , S Schwind
- , A-K Eisfeld
- , Y-Z Wu
- , B L Powell
- , T H Carter
- , M Wetzler
- , J E Kolitz
- , M R Baer
- , A J Carroll
- , R M Stone
- , M A Caligiuri
- , G Marcucci
- & C D Bloomfield
Leukemia 27 , 2023–2031

Rights & permissionsfor article A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia . Opens in a new window.
Research | 23 July 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
- J Etchin
- , J Montero
- , A Berezovskaya
- , B T Le
- , A Kentsis
- , A L Christie
- , A S Conway
- , W C Chen
- , C Reed
- , M R Mansour
- , C E L Ng
- , S Adamia
- , S J Rodig
- , I A Galinsky
- , R M Stone
- , B Klebanov
- , Y Landesman
- , M Kauffman
- , S Shacham
- , A L Kung
- , J C Y Wang
- , A Letai
- & A T Look
Leukemia 30 , 0–0

Rights & permissionsfor article Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice . Opens in a new window.
Research | 11 December 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
- S P Whitman
- , J Kohlschmidt
- , K Maharry
- , S Volinia
- , K Mrózek
- , D Nicolet
- , S Schwind
- , H Becker
- , K H Metzeler
- , J H Mendler
- , A-K Eisfeld
- , A J Carroll
- , B L Powell
- , T H Carter
- , M R Baer
- , J E Kolitz
- , I-K Park
- , R M Stone
- , M A Caligiuri
- , G Marcucci
- & C D Bloomfield
Leukemia 28 , 1252–1258

Rights & permissionsfor article GAS6 expression identifies high-risk adult AML patients: potential implications for therapy . Opens in a new window.
Research | 15 February 2011
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
- M R Baer
- , S L George
- , B L Sanford
- , K Mrózek
- , J E Kolitz
- , J O Moore
- , R M Stone
- , B L Powell
- , M A Caligiuri
- , C D Bloomfield
- & R A Larson
Leukemia 25 , 800–807

Rights & permissionsfor article Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 . Opens in a new window.
Research | 24 March 2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
- A-K Eisfeld
- , K Mrózek
- , J Kohlschmidt
- , D Nicolet
- , S Orwick
- , C J Walker
- , K W Kroll
- , J S Blachly
- , A J Carroll
- , J E Kolitz
- , B L Powell
- , E S Wang
- , R M Stone
- , A de la Chapelle
- , J C Byrd
- & C D Bloomfield
Leukemia 31 , 2211–2218

Rights & permissionsfor article The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia . Opens in a new window.
Research | 23 February 2015
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells
- H Bhanot
- , M M Reddy
- , A Nonami
- , E L Weisberg
- , D Bonal
- , P T Kirschmeier
- , S Salgia
- , K Podar
- , I Galinsky
- , T K Chowdary
- , D Neuberg
- , G Tonon
- , R M Stone
- , J Asara
- , J D Griffin
- & M Sattler
Leukemia 29 , 1555–1563

Rights & permissionsfor article Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells . Opens in a new window.
Research | 13 July 2015
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia
- H Wu
- , C Hu
- , A Wang
- , E L Weisberg
- , Y Chen
- , C-H Yun
- , W Wang
- , Y Liu
- , X Liu
- , B Tian
- , J Wang
- , Z Zhao
- , Y Liang
- , B Li
- , L Wang
- , B Wang
- , C Chen
- , S J Buhrlage
- , Z Qi
- , F Zou
- , A Nonami
- , Y Li
- , S M Fernandes
- , S Adamia
- , R M Stone
- , I A Galinsky
- , X Wang
- , G Yang
- , J D Griffin
- , J R Brown
- , M J Eck
- , J Liu
- , N S Gray
- & Q Liu
Leukemia 30 , 173–181

Rights & permissionsfor article Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia . Opens in a new window.
Research | 31 July 2014 | Open
Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
- D J DeAngelo
- , K E Stevenson
- , S E Dahlberg
- , L B Silverman
- , S Couban
- , J G Supko
- , P C Amrein
- , K K Ballen
- , M D Seftel
- , A R Turner
- , B Leber
- , K Howson-Jan
- , K Kelly
- , S Cohen
- , J H Matthews
- , L Savoie
- , M Wadleigh
- , L A Sirulnik
- , I Galinsky
- , D S Neuberg
- , S E Sallan
- & R M Stone
Leukemia 29 , 526–534

Rights & permissionsfor article Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia . Opens in a new window.
5 February 2004
Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome
- M A Sekeres
- , R M Stone
- , D Zahrieh
- , D Neuberg
- , V Morrison
- , D J De Angelo
- , I Galinsky
- & S J Lee
Leukemia 18 , 809–816

Rights & permissionsfor article Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome . Opens in a new window.
Research | 28 March 2013
SYK regulates mTOR signaling in AML
- J Carnevale
- , L Ross
- , A Puissant
- , V Banerji
- , R M Stone
- , D J DeAngelo
- , K N Ross
- & K Stegmaier
Leukemia 27 , 2118–2128

Rights & permissionsfor article SYK regulates mTOR signaling in AML . Opens in a new window.

Refine your results by…

Filters

Filter By:

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

No evidence for microsatellite instability in acute myeloid leukemia

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)

Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

Iron chelation therapy in myelodysplastic syndrome — Cui bono?

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

Induction and postremission therapy: new agents

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

SYK regulates mTOR signaling in AML

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters